Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06809868 · ClinicalTrials.gov registry record

Role of Transposable Elements in Septic Immune Aging

A clinical trial of Sepsis and Sepsis, Severe, sponsored by University of California, San Francisco.

Recruiting
Registry status
116
Enrollment target
1
Study location

NCT06809868: Recruiting study of Sepsis and Sepsis, Severe, sponsored by University of California, San Francisco.

NCT06809868 is a study of Sepsis and Sepsis, Severe that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 116 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06809868, a study of Sepsis and Sepsis, Severe, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
116 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU? Participants will have blood drawn from them but will not be subjected to additional interventions.

Conditions Studied

Sepsis Sepsis, Severe Sepsis, Septic Shock Sepsis and Septic Shock Sepsis With Multiple Organ Dysfunction (MOD) Sepsis With Acute Organ Dysfunction Sepsis at Intensive Care Unit Sepsis, Severe Sepsis and Septic Shock

Interventions

  • GENETIC RNA and DNA Sequencing

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2025-02-14
Est. Completion 2028-08-14
University of California, San Francisco

1,713 total trials

What NCT06809868 shows while recruiting

NCT06809868 is an observational study that tracks outcomes without assigning an intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).

The record links to 8 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which RNA and DNA Sequencing is the first listed.

NCT06809868 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06809868 about?

NCT06809868 is a clinical study titled "Role of Transposable Elements in Septic Immune Aging". The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is: 1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with i...

What is the current status of trial NCT06809868?

This trial is currently recruiting. The enrollment target is 116 participants. The study started on 2025-02-14. Estimated completion is 2028-08-14.

What conditions does trial NCT06809868 study?

This clinical trial studies the following conditions: Sepsis, Sepsis, Severe, Sepsis, Septic Shock, Sepsis and Septic Shock, Sepsis With Multiple Organ Dysfunction (MOD).

What interventions are being tested in trial NCT06809868?

The interventions under investigation include: RNA and DNA Sequencing (GENETIC).

Who is sponsoring clinical trial NCT06809868?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06809868 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06809868's enrollment target sits among peer trials

116 55th of 90 higher than 36 of 90 other Sepsis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03014687 · 116 participants · Phase 4

    Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

  • NCT03214562 · 116 participants · Phase 1

    Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

  • NCT03847467 · 116 participants · Phase 1

    Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

  • NCT04222413 · 116 participants · Phase 1

    Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06809868

Source: ClinicalTrials.gov NCT06809868, the US trial registry maintained by the National Library of Medicine. NCT06809868 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.